Open House Original Rebate Contracts 2025-05 - Emtricitabine/Tenofovir Disoproxil/Rilpivirine (Active Combination)
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-05 - Emtricitabin/Tenofovirdisoproxil/Rilpivirin (Wirkstoffkombination)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
Patent expiry or loss of market exclusivity automatically terminates the contract for the affected drug. This may resul...
No guaranteed sales volume or revenue; the rebate contract does not ensure actual prescriptions or market share.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Techniker Krankenkasse
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Feb 27, 2027
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Feb 2027
- Conclude rebate contracts for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine
- No individual negotiations; standard terms apply
Show full summary
This is an Open House procedure (not a public procurement) by Techniker Krankenkasse and other German health insurers to conclude rebate contracts under §130c SGB V for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine. The procedure is open continuously until the contract end date (28 February 2027) and all eligible pharmaceutical entrepreneurs with a valid marketing authorization for the drug combination can join on non-negotiable standard terms. No estimated value is published and no exclusivity is granted.
Risks
Patent expiry or loss of market exclusivity automatically terminates the contract for the affected drug. This may resul...
No guaranteed sales volume or revenue; the rebate contract does not ensure actual prescriptions or market share.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur under §4(18) AMG for the offered drug
- Must have a valid marketing authorization or be otherwise entitled to market the drug combination
- Must have registered seat within Germany, EU, or EEA
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Original Rebate Contracts 2025-05 - Emtricitabine/Tenofovir Disoproxil/Rilpivirine (Active Combination)
The objective is to conclude rebate contracts with all eligible pharmaceutical entrepreneurs for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine under uniform, non-negotiable conditions. The contract runs from 1 March 2025 to 28 February 2027 (max. 24 months), but ends automatically upon patent expiry or loss of market exclusivity.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Emtricitabin/Tenofovirdisoproxil/Rilpivirin zu schließen.
Value note
Show original TED data
Original lot title
Open House Originale Rabattverträge 2025-05 - Emtricitabin/Tenofovirdisoproxil/Rilpivirin (Wirkstoffkombination)
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Emtricitabin/Tenofovirdisoproxil/Rilpivirin zu schließen.
Procurement Details
- Publication date
- 20 Jan 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 40386-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
Patent expiry or loss of market exclusivity automatically terminates the contract for the affected drug. This may resul...
No guaranteed sales volume or revenue; the rebate contract does not ensure actual prescriptions or market share.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications